The elderly Secondary prevention
Introduction
Stroke is a major cause of morbidity and mortality worldwide. The incidence of stroke in Poland is estimated at 175 per 100,000 for men and 125 per 100,000 for women and is similar to other European countries but the mortality is greater [1] [2] [3] [4] [5] . A history of a previous stroke is an important risk factor for subsequent cerebrovascular incidents. The most commonly used drugs worldwide in secondary prevention of stroke are oral antiplatelet agents (OAP), and among them -acetylsalicylic acid (ASA) [6] . The occurrence of cerebrovascular incidents has been reduced by 25% in patients regularly taking ASA [7, 8] . Another group of medications used in secondary prevention are oral anticoagulant (OAC) drugs, especially recommended for prevention of recurrent stroke in people with atrial fibrillation [9] .
The incidence of stroke increases significantly with age, and age is considered to be the strongest risk factor for cerebrovascular disease. Little is known about the usage of OAPs and OACs as the secondary prevention of stroke by the elderly in our country.
Thus, the purpose of the study was to evaluate the frequency of use of OAP and OAC drugs as secondary stroke prevention among older people in Poland and its association with clinical characteristics and concomitant cardiovascular risk factors.
Materials and methods
The study was based on the data collected during the implementation of a multicentre, publicly funded research project commissioned by the Polish Ministry of Science and Higher Education called 'Medical, psychological, sociological and economic aspects of ageing of people in Poland (PolSenior)' (PBZ-MEiN-9/2/2006). A detailed description of the project has been previously published [10, 11] . The project was carried out from October 2008 to April 2012. It was approved by the Bioethics Commission of the Medical University of Silesia in Katowice. The study group included respondents from the PolSenior project aged 65 years and older who answered positively to the question: 'Have you ever been hospitalized because of a stroke?' The following data from the general PolSenior database were used and analysed: age, sex, place of residence (village or city, or staying at a nursing home), level of education, personal income, a history of cardiovascular risk factors (coronary heart disease, previous myocardial infarction, congestive heart failure, pharmacologically treated hypertension, a history of atrial fibrillation, another previous stroke, pharmacologically treated diabetes, pharmacologically treated dyslipidaemia, active smoking), body mass index. The frequency of use of drugs was based on the data collected in the medical part of the questionnaire, including the international and trade names of drugs taken by participants.
Statistical data analysis was performed using SAS version 9.2 (SAS Institute Inc., Gary, NC). The level of statistical Table 2 -Oral antiplatelet drugs (OAPs) and oral anticoagulant drugs (OACs) usage after stroke in different regions of Poland.
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Results
Among all the PolSenior participants aged 65 and older (n = 4979), 426 people (8.6%) answered 'Yes' to the question: 'Have you ever been hospitalized because of a stroke?' and they were included in the analysis. The study group consisted of 236 men (55.4%) and 190 women (44.6%). The mean age of the examined subjects was 81.5 AE 8.2 years, similar for men and women (81.1 AE 8.7 vs. 81.9 AE 7.5 years p = 0.33, respectively). Among all the patients with a history of a stroke, 261 subjects (61.3%) used at least one drug as the secondary prevention. Oral antiplatelets were regularly used by 237 people (55.6%); 224 (94.5%) were taking one drug, and 13 (5.5%) were taking two drugs. Oral anticoagulants were regularly used by 25 subjects (5.9%) (one respondent was taking two OACs). Antiplatelet therapy and anticoagulant therapy were simultaneously applied by only one person ( Table 1) .
The percentage of women after stroke using OAPs and/or OACs (61.1%; n = 116) was similar to the corresponding percentage of men after stroke (61.4%; n = 145) ( p = 0.93). Also 
the age of the respondents did not affect the prevalence of secondary stroke prevention. Most of analysed group lived in cities (61.2%; n = 264). There was no difference in using OAP and/or OAC drugs between urban (61.4%; n = 162) and rural (61.1%; n = 99) residents ( p = 0.96). In the study group, there were 8 residents of nursing houses (1.9%) and 5 of them (62.5%) used OAP and/or OAC drugs.
We observed significant differences in the frequency of usage of antiplatelet drugs, depending on the province where the respondents lived. Oral antiplatelets were mostly applied by people from East (65.9% of respondents living in this region) and South (63.2%), while the lowest amount was applied by people living in Central region (45.7%), and North-West (48.4%). A detailed analysis of OAPs and/or OACs usage in different Polish regions is presented in Table 2 .
No correlation was found between the frequency of use of OAPs and/or OACs after stroke and the level of education (Table 3 ) or personal income (Table 4) .
The frequency of cardiovascular risk factors in the whole study group is shown in Table 5 . The association between use of OAP and/or OAC drugs and presence or absence of cardiovascular risk factors is presented in Table 6 . Among all of the cardiovascular risk factors, congestive heart failure was most associated with OAP treatment, and a history of atrial fibrillation-with OAC treatment (Table 7) .
Discussion
The study was based on a countrywide representative sample of Poles aged 65 years or older and presented the prevalence of secondary preventive therapy among a group of respondents after at least one episode of stroke. We found that in Poland about 60% of older people after stroke were applying secondary pharmacological prevention, and it seemed to be less than in other Western European countries [12] [13] [14] , especially in people with atrial fibrillation [12] . Only one fifth of older Polish people with atrial fibrillation used OACs. According to the Swedish Stroke Register more than 30% of people after stroke with atrial fibrillation are applying OACs [12] . It should be stressed that the Swedish Stroke Register population was younger than in our study (mean age about 75 years). Both worldwide and in Poland, the most popular drug used as secondary cardiovascular prevention is ASA. We also observed that ticlopidine was used more frequently in Poland than clopidogrel, probably because of the financial reasons (until recently, the preparations of clopidogrel in Poland were much more expensive than ticlopidine). Dual antiplatelet therapy was used by about 5% of respondents and the most common combination was ASA with ticlopidine.
We found that dipyridamole was not at all used in Poland. This drug is recommended in combination with ASA in patients after stroke who used ASA before or in patients after recurrent strokes [15, 16] . The monthly cost of such combination is much higher than the therapy with ASA alone. In our country, not only the price, but also low availability of dipyridamole (it is not dispensed in Polish pharmacies), poses the problem. For instance, in Sweden it is prescribed in more than 10% of people discharged from the hospital after an ischaemic stroke [13] .
We noticed that acenocoumarol was much more popular than warfarin in Poland, contrary to the situation in other 
countries [12] [13] [14] . In our opinion, it was also associated with low availability and high price of the drug for the patient in the period when the study was conducted. Contrary to our previous paper [17] , concerning general usage of OAPs and OACs in the whole PolSenior population, we found no association between applying of secondary cardiovascular prevention and age, sex, place of residence, level of education, and personal income.
However, our study revealed significant differences in the frequency of usage of analysed drugs, depending on the region where the respondents lived. In some regions, the prevalence of secondary pharmacological prevention was much lower than the average. It especially concerned Central region and North-West region. The number of people living in particular regions was rather low and it might influence the statistics but it should be checked in further examinations.
5.
Limitations of the study
The reasons for abandonment of therapy (contraindications), the type of the stroke (ischaemic or haemorrhagic), and the time from the stroke could not be established because of the lack of data.
Conclusions
1. In Poland secondary cardiovascular preventive therapy is used too rarely in older people after stroke, and it especially concerns anticoagulant therapy in those with a history of atrial fibrillation. 2. The frequency of use of OAPs and OACs as the secondary prevention in elderly people is not associated with age, sex, place of residence (urban or rural), level of education, and personal income. 3. The usage of OACs and/or OACs depends on the region where the respondents lived. 4. Among all the analysed drugs, the most popular is ASA.
Ticlopidine is more popular than clopidogrel, and acenocoumarol-than warfarin. Dipiridamole is not used in Poland as secondary prevention. 5. Among all of the concomitant cardiovascular risk factors, congestive heart failure was most associated with OAP treatment in the elderly after stroke, and a history of atrial fibrillation-with OAC treatment. Structured educational programmes should be developed in our country to improve usage of secondary preventive therapy in the elderly.
